These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19664042)

  • 21. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
    Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells.
    Dai B; Chen H; Guo S; Yang X; Linn DE; Sun F; Li W; Guo Z; Xu K; Kim O; Kong X; Melamed J; Qiu S; Chen H; Qiu Y
    Cancer Res; 2010 Jul; 70(13):5587-96. PubMed ID: 20570899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serine threonine tyrosine kinase 1 is a potential prognostic marker in colorectal cancer.
    Hu L; Chen HY; Cai J; Zhang Y; Qi CY; Gong H; Zhai YX; Fu H; Yang GZ; Gao CF
    BMC Cancer; 2015 Apr; 15():246. PubMed ID: 25884558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation.
    Brown NE; Paluch AM; Nashu MA; Komurov K; Waltz SE
    Neoplasia; 2018 Sep; 20(9):917-929. PubMed ID: 30121008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC).
    Li Y; Shi H; Zhao Z; Xu M
    BMC Urol; 2022 Oct; 22(1):162. PubMed ID: 36258196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. STYK1/NOK Promotes Metastasis and Epithelial-Mesenchymal Transition in Non-small Cell Lung Cancer by Suppressing FoxO1 Signaling.
    Lai Y; Lin F; Wang X; Zhang J; Xia J; Sun Y; Wen M; Li X; Zhang Z; Zhao J
    Front Cell Dev Biol; 2021; 9():621147. PubMed ID: 34295886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling.
    Brown NE; Jones A; Hunt BG; Waltz SE
    Prostate; 2022 Nov; 82(15):1422-1437. PubMed ID: 35860905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.
    Chen S; Cai C; Sowalsky AG; Ye H; Ma F; Yuan X; Simon NI; Gray NS; Balk SP
    Cancer Res; 2018 Sep; 78(18):5203-5215. PubMed ID: 30012673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
    Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
    Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.
    Offermann A; Vlasic I; Syring I; Vogel W; Ruiz C; Zellweger T; Rentsch CA; Hagedorn S; Behrends J; Nowak M; Merseburger A; Bubendorf L; Kirfel J; Duensing S; Adler D; Perner S
    Oncotarget; 2017 Jan; 8(5):7964-7976. PubMed ID: 27974704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Depletion of STYK1 inhibits intrahepatic cholangiocarcinoma development both in vitro and in vivo.
    Chen MY; Zhang H; Jiang JX; Sun CY; Yu C; Tian S
    Tumour Biol; 2016 Oct; 37(10):14173-14181. PubMed ID: 27542675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer.
    Adler D; Menon R; Braun M; Offermann A; Queisser A; Boehm D; Vogel W; Rüenauver K; Ruiz C; Zellweger T; Svensson M; Andren O; Kristiansen G; Wernert N; Bubendorf L; Kirfel J; Biskup S; Perner S
    Int J Cancer; 2014 Jul; 135(1):19-26. PubMed ID: 24374838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
    D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
    Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
    Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
    Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer.
    Xu B; Wang N; Wang X; Tong N; Shao N; Tao J; Li P; Niu X; Feng N; Zhang L; Hua L; Wang Z; Chen M
    Prostate; 2012 Aug; 72(11):1171-8. PubMed ID: 22161865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
    Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
    Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
    Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL
    Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of serine threonine tyrosine kinase 1 as a drug resistance factor and therapeutic predictor in acute leukemia.
    Nirasawa S; Kobayashi D; Kondoh T; Kuribayashi K; Tanaka M; Yanagihara N; Watanabe N
    Int J Oncol; 2014 Nov; 45(5):1867-74. PubMed ID: 25190507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer.
    Sircar K; Huang H; Hu L; Cogdell D; Dhillon J; Tzelepi V; Efstathiou E; Koumakpayi IH; Saad F; Luo D; Bismar TA; Aparicio A; Troncoso P; Navone N; Zhang W
    Am J Pathol; 2012 Mar; 180(3):895-903. PubMed ID: 22245216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.